Clinical Implications of VEGF, TGF-β1, and IL-1β in Patients with Advanced Non-small Cell Lung Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Vascular endothelial growth factor (VEGF)-A, VEGF165b, interleukin (IL)-1β, and transforming growth factor (TGF)-β1 are known to influence tumor angiogenesis. Clinical implications of these cytokines need to be elucidated. Materials and Methods Using clinical data and baseline serum samples of 140 consecutive patients with advanced non-small cell lung cancer who received platinum-based combination chemotherapy, we investigated the association among serum cytokine levels, treatment outcomes, as well as leukocyte and platelet counts. Results The median age of patients was 64 years (range, 26 to 86 years). The male to female ratio was 104:36. High TGF-β1 and IL-1β levels were associated with shorter progression-free survival, and high VEGF-A and IL-1β levels were associated with shorter overall survival in the univariate analysis. VEGF165b was not related to the treatment outcomes. Leukocytosis and thrombocytosis were associated with shorter overall survival. The multivariate analysis demonstrated that VEGF-A, IL-1β, and leukocytosis were significant prognostic factors (p=0.0497, p=0.047, and p<0.001, respectively). Leukocytosis was not associated with recent pneumonia (p=0.937) and correlated with VEGF-A (p<0.001) and TGF- β1 (p=0.020) levels. Conclusion Serum VEGF-A, TGF-1β, and IL-1β levels, in addition to leukocyte and platelet counts,are shown to be associated with clinical outcomes. Leukocyte and platelet counts are correlated with serum VEGF-A and TGF-β1 levels.
Abstract
Purpose Vascular endothelial growth factor (VEGF)-A, VEGF165b, interleukin (IL)-1β, and transforming growth factor (TGF)-β1 are known to influence tumor angiogenesis. Clinical implications of these cytokines need to be elucidated. Materials and Methods Using clinical data and baseline serum samples of 140 consecutive patients with advanced non-small cell lung cancer who received platinum-based combination chemotherapy, we investigated the association among serum cytokine levels, treatment outcomes, as well as leukocyte and platelet counts. Results The median age of patients was 64 years (range, 26 to 86 years). The male to female ratio was 104:36. High TGF-β1 and IL-1β levels were associated with shorter progression-free survival, and high VEGF-A and IL-1β levels were associated with shorter overall survival in the univariate analysis. VEGF165b was not related to the treatment outcomes. Leukocytosis and thrombocytosis were associated with shorter overall survival. The multivariate analysis demonstrated that VEGF-A, IL-1β, and leukocytosis were significant prognostic factors (p=0.0497, p=0.047, and p<0.001, respectively). Leukocytosis was not associated with recent pneumonia (p=0.937) and correlated with VEGF-A (p<0.001) and TGF- β1 (p=0.020) levels. Conclusion Serum VEGF-A, TGF-1β, and IL-1β levels, in addition to leukocyte and platelet counts,are shown to be associated with clinical outcomes. Leukocyte and platelet counts are correlated with serum VEGF-A and TGF-β1 levels.
참고문헌 (25)
- Poon RT, "Clinical implications of circulating angiogenic factors in cancer patients", J Clin Oncol, 19, pp.1207~1225 (2001)
- Shchors K, "Tumor angiogenesis: cause or consequence of cancer", Cancer Res, 67, pp.7059~7061 (2007)
- Bremnes RM, "Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood", Lung Cancer, 51, pp.143~158 (2006)
- Woolard J, "VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression", Cancer Res, 64, pp.7822~7835 (2004)
- Pepper MS, "Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity", Cytokine Growth Factor Rev, 8, pp.21~43 (1997)
- Pertovaara L, "Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells", J Biol Chem, 269, pp.6271~6274 (1994)
- Hasegawa Y, "Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma", Cancer, 91, pp.964~971 (2001)
- Raynal S, "Transforming growth factor-beta1 enhances the lethal effects of DNA-damaging agents in a human lung-cancer cell line", Int J Cancer, 72, pp.356~361 (1997)
- Chod J, "Preoperative transforming growth factor-beta 1 (TGF-beta 1) plasma levels in operable breast cancer patients", Eur J Gynaecol Oncol, 29, pp.613~616 (2008)
- Shariat SF, "Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression", Clin Cancer Res, 10, pp.1992~1999 (2004)
- Ivanovic V, "Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression", Eur J Cancer, 39, pp.454~461 (2003)
- Zeisler H, "Serum interleukin 1 in ovarian cancer patients", Eur J Cancer, 34, pp.931~933 (1998)
- Salven P, "Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor", Clin Cancer Res, 5, pp.487~491 (1999)
- Assoian RK, "Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization", J Biol Chem, 258, pp.7155~7160 (1983)
- Letterio JJ, "Regulation of immune responses by TGF-beta", Annu Rev Immunol, 16, pp.137~161 (1998)
- Dinarello CA, "The interleukin-1 family: 10 years of discovery", FASEB J, 8, pp.1314~1325 (1994)
- Choi JH, "Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts", Lung Cancer, 33, pp.171~179 (2001)
- Brattstrom D, "Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients", Lung Cancer, 37, pp.57~63 (2002)
- Beasley MB, "The 2004 World Health Organization classification of lung tumors", Semin Roentgenol, 40, pp.90~97 (2005)
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
- Foekens JA, "High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer", Cancer Res, 61, pp.5407~5414 (2001)
- Ladomery MR, "Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm", Cancer Lett, 249, pp.133~142 (2007)
- Mohle R, "Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets", Proc Natl Acad Sci U S A, 94, pp.663~668 (1997)
- Wartiovaara U, "Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation", Thromb Haemost, 80, pp.171~175 (1998)
- Lee JK, "Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen", Int J Oncol, 17, pp.149~152 (2000)